About Nubytide (8M2D)

• Large, growing market - $3.5B+ with 7.4M US patients

• Differentiated technology - disease modifying

• Enrolling first participant in late 2026

• Affordable, easy to administer

Strong IP position

• 9 issued US patents

• 10 issued international patents

Nubytide reduces Aß, markers of inflammation and Tau pathology

Nubytide (8M2D) Mission and Vision

Global
Solution

Disease Modifying

Better Alternative

Reduces Aß Markers

Mission: Make Nubytide available to every patient in the world suffering from Alzheimer's Disease.

Mission: Nubytide is the proactive therapy to delay or stop the onset of the disease to anyone over the age of 65.

Vision: Alzheimer Disease drugs today are monoclonal antibodies which come with higher costs, are harder to administer and are less safe.

Vision: Why Nubytide? Nubytide is a peptide drug which reduces Aß, markers of inflammation and Tau pathology.

Alzheimer's Disease

Alzheimer's Disease is a growing global epidemic

Global Market

• Worldwide, at least 55 million people are believed to be living with Alzheimer's disease or other dementias.

• According to the United Nations, that is more than the population of Colombia.

• If breakthroughs are not discovered, this number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050.

• One in three seniors dies with Alzheimer's or related dementia.

Bright Focus Foundation – Alzheimer’s Facts and Figures

Investor Opportunity

Cenna is Poised to Quickly Move Nubytide (8M2D) Through Clinical Trials to Exit Phases

Cenna Biosciences Team

Cenna has assembled a team of seasoned biopharmaceuticalspecialists:

Nazneen Dewji, Ph.D.
Founder, President and CEO

Christine Smith, Ph.D.
CMC

Robert Alexander, MD
CMO

Archie W. Thurston, Jr.,
Ph.D. ADME.
Pharmacology Consultant

Grace Furman, Ph.D.
D.A.B.T., Toxicology
President and CEO,
Paracelcus

Karlene Cork, Ph.D.
Regulatory Affairs

News

Cenna Announces Appointment of David H. Crean to Board of Directors

Press Release - December 19th 2023

Cardiff Advisory Managing Partner Has Decades of Experience Guiding Life Sciences and Healthcare Companies Through Pivotal Growth, Won the Alzheimer’s Association of San Diego 2023 Hope Award and Has Been Recognized as One of San Diego’s 500 Most Influential People for the Last Four Years.

Cenna Biosciences Receives NIH NIA Phase II SBIR Award for the Early Clinical Development of Nubytide TM, a First-in-Class, Disease-Modifying Peptide Drug for the Prevention and Treatment of Alzheimer’s Disease

Press Release - September 23rd 2024

Cenna Biosciences Inc., a privately-held biopharmaceutical company based in La Jolla, California, and focused on developing novel treatments for Alzheimer's disease (AD), has been awarded a Phase II SBIR grant of $2.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA), to support the early clinical development of their peptide drug NubytideTM, for the prevention and treatment of AD. AD is a complex disorder for which there are few treatments. There are 55 million people living with AD worldwide, and 6 million in the U.S. alone. The prevalence of AD is expected to grow at a rate of 2.5% per year in the seven major pharmaceutical markets of the world. New medications to prevent the onset, delay progression, or improve symptoms of AD are urgently needed.

Cenna Biosciences Receives FDA Clearance to Begin Phase 1a/1b Clinical Trial of 8M2D, a First-in-Class Peptide Designed to Stop the Production of Amyloid in Alzheimer's Disease

Press Release - June 17th 2026

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of Cenna Biosciences (Cenna) to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide for the treatment of Alzheimer's disease (AD). 8M2D is designed to address the root cause of AD by inhibiting the production of β-amyloid (Aβ), rather than clearing it after it has already accumulated in the brain. "FDA clearance of our IND is a defining milestone for Cenna," said Nazneen Dewji, Ph.D., Chief Executive Officer of Cenna. "The amyloid-targeting therapies approved to date all work by clearing plaque after it has formed. 8M2D is designed to intervene earlier in the disease process, by stopping amyloid from being produced. This clearance allows us to test that approach in people, and we expect to dose our first participant in late 2026."

Contact Cenna

Email

ndewji@cennabiosciences.com

Phone

(858)-456-0820

Address

505 Coast S Blvd, Suite 307a, La Jolla, CA 92037, United States

Cenna Biosciences Inc.
505 Coast S Blvd, Suite 307a, La Jolla, CA 92037
© All Rights Reserved - Cenna Biosciences 2026
ndewji@cennabiosciences.com
(858)-456-0820
Privacy Policy
Terms of Use